The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer

Cancer Treatment Reviews

Volumn 38, Issue 5, 2012, Pages 451-466

  Roxburgh, C S D ^a   McMillan, D C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Colorectal cancer; Immune cells; In situ response; Recurrence and survival; Tumour inflammatory infiltrate

Indexed keywords

ANTINEOPLASTIC AGENT; CD133 ANTIGEN; CD16 ANTIGEN; CD161 ANTIGEN; CD20 ANTIGEN; CD45RO ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; CD68 ANTIGEN; CD83 ANTIGEN; DENDRITIC CELL LYSOSOME ASSOCIATED MEMBRANE PROTEIN; ELASTASE; PROTEIN S 100; TRANSCRIPTION FACTOR FOXP3;

ANTIGEN EXPRESSION; B LYMPHOCYTE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL DENSITY; CELL SURVIVAL; COLORECTAL CANCER; COLORECTAL SURGERY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE FREE SURVIVAL; EOSINOPHIL; HELPER CELL; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFLAMMATION; INFLAMMATORY CELL; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MAST CELL; MEMORY T LYMPHOCYTE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MULTIMODALITY CANCER THERAPY; NATURAL KILLER CELL; NEUTROPHIL; OVERALL SURVIVAL; POLYMORPHONUCLEAR CELL; PREDICTIVE VALUE; QUANTITATIVE ANALYSIS; REGULATORY T LYMPHOCYTE; REVIEW; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGENS, CD3; ANTIGENS, CD45; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COLORECTAL NEOPLASMS; DENDRITIC CELLS; DISEASE PROGRESSION; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MICROSATELLITE INSTABILITY; NEUTROPHILS; PREDICTIVE VALUE OF TESTS;

EID: 84861194756     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.09.001     Document Type: Review

References (111)

1. CRUK CR. Bowel Cancer-UK incidence statistics. Available from: 2004 [cited 04.04.11]. http://info.cancerresearch.org/cancerstats/types/bowel/incidence.
2. McArdle C.S., Hole D.J. Outcome following surgery for colorectal cancer: analysis by hospital after adjustment for case-mix and deprivation. Br J Cancer 2002, 86(3):331-335.
3. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30(7):1073-1081.
4. Roxburgh C.S., McMillan D.C. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010, 6(1):149-163.
5. Read J.A., Choy S.T., Beale P.J., Clarke S.J. Evaluation of nutritional and inflammatory status of advanced colorectal cancer patients and its correlation with survival. Nutr Cancer 2006, 55(1):78-85.
6. Leitch E.F., Chakrabarti M., Crozier J.E., McKee R.F., Anderson J.H., Horgan P.G., et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer 2007, 97(9):1266-1270.
7. Malik H.Z., Prasad K.R., Halazun K.J., Aldoori A., Al-Mukhtar A., Gomez D., et al. Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Ann Surg 2007, 246(5):806-814.
8. Ishizuka M., Nagata H., Takagi K., Kubota K. Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer. Ann Surg 2009, 250(2):268-272.
9. Sharma R., Zucknick M., London R., Kacevska M., Liddle C., Clarke S.J. Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clin Colorectal Cancer 2008, 7(5):331-337.
10. Peltomaki P. The genetics of hereditary non-polyposis colorectal cancer and non-polypotic colon cancer. Adv Exp Med Biol 1999, 470:95-98.
11. Boland C.R., Thibodeau S.N., Hamilton S.R., Sidransky D., Eshleman J.R., Burt R.W., et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998, 58(22):5248-5257.
12. Boland C.R., Sato J., Saito K., Carethers J.M., Marra G., Laghi L., et al. Genetic instability and chromosomal aberrations in colorectal cancer: a review of the current models. Cancer Detect Prev 1998, 22(5):377-382.
13. Jass J.R., Do K.A., Simms L.A., Iino H., Wynter C., Pillay S.P., et al. Morphology of sporadic colorectal cancer with DNA replication errors. Gut 1998, 42(5):673-679.
14. Michael-Robinson J.M., Biemer-Huttmann A., Purdie D.M., Walsh M.D., Simms L.A., Biden K.G., et al. Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status. Gut 2001, 48(3):360-366.
15. Sinicrope F.A., Rego R.L., Ansell S.M., Knutson K.L., Foster N.R., Sargent D.J. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 2009, 137(4):1270-1279.
16. Baker K., Zlobec I., Tornillo L., Terracciano L., Jass J.R., Lugli A. Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: a potential role for dysregulation of the transforming growth factor-beta pathway. Eur J Cancer 2007, 43(3):624-631.
17. Laghi L., Bianchi P., Miranda E., Balladore E., Pacetti V., Grizzi F., et al. CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol 2009, 10(9):877-884.
18. Deschoolmeester V., Baay M., Van Marck E., Weyler J., Vermeulen P., Lardon F., et al. Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol 2010, 11:19.
19. Dahlin A.M., Henriksson M.L., Van Guelpen B., Stenling R., Oberg A., Rutegard J., et al. Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. Mod Pathol. 2011, 24(5):671-682.
20. Spratt J.S.S.H. Prevalence and prognosis of individual clinical and pathologic variables associated with colorectal carcinoma. Cancer 1967, 20:1976-1985.
21. Murray D., Hreno A., Dutton J., Hampson L.G. Prognosis in colon cancer: a pathologic reassessment. Arch Surg 1975, 110(8):908-913.
22. Zamcheck N., Doos W.G., Prudente R., Lurie B.B., Gottlieb L.S. Prognostic factors in colon carcinoma: correlation of serum carcinoembryonic antigen level and tumor histopathology. Hum Pathol 1975, 6(1):31-45.
23. Watt A.G., House A.K. Colonic carcinoma: a quantitative assessment of lymphocyte infiltration at the periphery of colonic tumors related to prognosis. Cancer 1978, 41(1):279-282.
24. House A.K., Watt A.G. Survival and the immune response in patients with carcinoma of the colorectum. Gut 1979, 20(10):868-874.
25. Thynne G.S., Weiland L.H., Moertel C.G., Silvers A. Correlation of histopathologic characteristics of primary tumor and uninvolved regional lymph nodes in Dukes' class C colonic carcinoma with prognosis. Mayo Clin Proc 1980, 55(4):243-245.
26. de Mascarel A., Coindre J.M., de Mascarel I., Trojani M., Maree D., Hoerni B. The prognostic significance of specific histologic features of carcinoma of the colon and rectum. Surg Gynecol Obstet 1981, 153(4):511-514.
27. Zhou X.G., Yu B.M., Shen Y.X. Surgical treatment and late results in 1226 cases of colorectal cancer. Dis Colon Rectum 1983, 26(4):250-256.
28. Svennevig J.L., Lunde O.C., Holter J., Bjorgsvik D. Lymphoid infiltration and prognosis in colorectal carcinoma. Br J Cancer 1984, 49(3):375-377.
29. Carlon C.A., Fabris G., Arslan-Pagnini C., Pluchinotta A.M., Chinelli E., Carniato S. Prognostic correlations of operable carcinoma of the rectum. Dis Colon Rectum 1985, 28(1):47-50.
30. Jass J.R. Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol 1986, 39(6):585-589.
31. Jass J.R., Love S.B., Northover J.M. A new prognostic classification of rectal cancer. Lancet 1987, 1(8545):1303-1306.
32. Halvorsen T.B., Seim E. Tumour site: a prognostic factor in colorectal cancer? A multivariate analysis. Scand J Gastroenterol 1987, 22(1):124-128.
33. Adachi Y., Mori M., Kuroiwa S., Sugimachi K., Enjoji M. Histopathologic evaluation of survival time in patients with colorectal carcinoma. J Surg Oncol 1989, 42(4):219-224.
34. Graham D.M., Appelman H.D. Crohn's-like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator. Mod Pathol 1990, 3(3):332-335.
35. Di Giorgio A., Botti C., Tocchi A., Mingazzini P., Flammia M. The influence of tumor lymphocytic infiltration on long term survival of surgically treated colorectal cancer patients. Int Surg 1992, 77(4):256-260.
36. Kubota Y., Sunouchi K., Ono M., Sawada T., Muto T. Local immunity and metastasis of colorectal carcinoma. Dis Colon Rectum. 1992, 35(7):645-650.
37. Harrison J.C., Dean P.J., el-Zeky F., Vander Zwaag R. From Dukes through Jass: pathological prognostic indicators in rectal cancer. Hum Pathol 1994, 25(5):498-505.
38. Coca S., Perez-Piqueras J., Martinez D., Colmenarejo A., Saez M.A., Vallejo C., et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997, 79(12):2320-2328.
39. Cianchi F., Messerini L., Palomba A., Boddi V., Perigli G., Pucciani F., et al. Character of the invasive margin in colorectal cancer: does it improve prognostic information of Dukes staging?. Dis Colon Rectum 1997, 40(10):1170-1175. [discussion 5-6].
40. Adams W.J., Morris D.L. Pilot study - cimetidine enhances lymphocyte infiltration of human colorectal carcinoma: results of a small randomized control trial. Cancer 1997, 80(1):15-21.
41. Ropponen K.M., Eskelinen M.J., Lipponen P.K., Alhava E., Kosma V.M. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 1997, 182(3):318-324.
42. Diez M., Pollan M., Enriquez J.M., Dominguez P., Santana A., Tobaruela E., et al. Histopathologic prognostic score in colorectal adenocarcinomas. Anticancer Res 1998, 18(1B):689-694.
43. Kelly M.D., King J., Cherian M., Dwerryhouse S.J., Finlay I.G., Adams W.J., et al. Randomized trial of preoperative cimetidine in patients with colorectal carcinoma with quantitative assessment of tumor-associated lymphocytes. Cancer 1999, 85(8):1658-1663.
44. Nielsen H.J., Hansen U., Christensen I.J., Reimert C.M., Brunner N., Moesgaard F. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol 1999, 189(4):487-495.
45. Murphy J., O'Sullivan G.C., Lee G., Madden M., Shanahan F., Collins J.K., et al. The inflammatory response within Dukes' B colorectal cancers: implications for progression of micrometastases and patient survival. Am J Gastroenterol 2000, 95(12):3607-3614.
46. Nagtegaal I.D., Marijnen C.A., Kranenbarg E.K., Mulder-Stapel A., Hermans J., van de Velde C.J., et al. Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect - a histopathological and immunohistochemical study. BMC Cancer 2001, 1:7.
47. Cianchi F., Palomba A., Messerini L., Boddi V., Asirelli G., Perigli G., et al. Tumor angiogenesis in lymph node-negative rectal cancer: correlation with clinicopathological parameters and prognosis. Ann Surg Oncol 2002, 9(1):20-26.
48. Chiba T., Ohtani H., Mizoi T., Naito Y., Sato E., Nagura H., et al. Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. Br J Cancer 2004, 91(9):1711-1717.
49. Buckowitz A., Knaebel H.P., Benner A., Blaker H., Gebert J., Kienle P., et al. Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br J Cancer 2005, 92(9):1746-1753.
50. Klintrup K., Makinen J.M., Kauppila S., Vare P.O., Melkko J., Tuominen H., et al. Inflammation and prognosis in colorectal cancer. Eur J Cancer 2005, 41(17):2645-2654.
51. Gao J.F., Arbman G., Wadhra T.I., Zhang H., Sun X.F. Relationships of tumor inflammatory infiltration and necrosis with microsatellite instability in colorectal cancers. World J Gastroenterol 2005, 11(14):2179-2183.
52. Szynglarewicz B., Matkowski R., Suder E., Sydor D., Forgacz J., Pudelko M., et al. Predictive value of lymphocytic infiltration and character of invasive margin following total mesorectal excision with sphincter preservation for the high-risk carcinoma of the rectum. Adv Med Sci 2007, 52:159-163.
53. Forssell J., Oberg A., Henriksson M.L., Stenling R., Jung A., Palmqvist R. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 2007, 13(5):1472-1479.
54. Morris M., Platell C., Iacopetta B. Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. Clin Cancer Res 2008, 14(5):1413-1417.
55. Roxburgh C.S., Salmond J.M., Horgan P.G., Oien K.A., McMillan D.C. Tumour inflammatory infiltrate predicts survival following curative resection for node-negative colorectal cancer. Eur J Cancer 2009, 45(12):2138-2145.
56. Roxburgh C.S., Salmond J.M., Horgan P.G., Oien K.A., McMillan D.C. Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Ann Surg 2009, 249(5):788-793.
57. Ogino S., Nosho K., Irahara N., Meyerhardt J.A., Baba Y., Shima K., et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 2009, 15(20):6412-6420.
58. Chang E.Y., Dorsey P.B., Frankhouse J., Lee R.G., Walts D., Johnson W., et al. Combination of microsatellite instability and lymphocytic infiltrate as a prognostic indicator in colon cancer. Arch Surg 2009, 144(6):511-515.
59. McCarty W. Principles of prognosis in cancer. JAMA 1931, 96:30-33.
60. Jass J.R. The pathological classification of colorectal cancer. Ann Acad Med Singapore 1987, 16(3):469-473.
61. Smyrk T.C., Watson P., Kaul K., Lynch H.T. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer 2001, 91(12):2417-2422.
62. Alexander J., Watanabe T., Wu T.T., Rashid A., Li S., Hamilton S.R. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol 2001, 158(2):527-535.
63. Greenson J.K., Bonner J.D., Ben-Yzhak O., Cohen H.I., Miselevich I., Resnick M.B., et al. Phenotype of microsatellite unstable colorectal carcinomas: well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. Am J Surg Pathol 2003, 27(5):563-570.
64. Roxburgh C.S., Salmond J.M., Horgan P.G., Oien K.A., McMillan D.C. The relationship between the local and systemic inflammatory responses and survival in patients undergoing curative surgery for colon and rectal cancers. J Gastrointest Surg 2009, 13(11):2011-2018. [discussion 8-9].
65. Guidoboni M., Gafa R., Viel A., Doglioni C., Russo A., Santini A., et al. Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol 2001, 159(1):297-304.
66. Takemoto N., Konishi F., Yamashita K., Kojima M., Furukawa T., Miyakura Y., et al. The correlation of microsatellite instability and tumor-infiltrating lymphocytes in hereditary non-polyposis colorectal cancer (HNPCC) and sporadic colorectal cancers: the significance of different types of lymphocyte infiltration. Jpn J Clin Oncol 2004, 34(2):90-98.
67. Baeten C.I., Castermans K., Hillen H.F., Griffioen A.W. Proliferating endothelial cells and leukocyte infiltration as prognostic markers in colorectal cancer. Clin Gastroenterol Hepatol 2006, 4(11):1351-1357.
68. Lackner C., Jukic Z., Tsybrovskyy O., Jatzko G., Wette V., Hoefler G., et al. Prognostic relevance of tumour-associated macrophages and von Willebrand factor-positive microvessels in colorectal cancer. Virchows Arch 2004, 445(2):160-167.
69. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313(5795):1960-1964.
70. Peng R.Q., Chen Y.B., Ding Y., Zhang R., Zhang X., Yu X.J., et al. Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer. World J Gastroenterol 2010, 16(19):2428-2434.
71. Nosho K., Baba Y., Tanaka N., Shima K., Hayashi M., Meyerhardt J.A., et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 2010, 222(4):350-366.
72. Lee W.S., Park S., Lee W.Y., Yun S.H., Chun H.K. Clinical impact of tumor-infiltrating lymphocytes for survival in stage II colon cancer. Cancer 2010, 116(22):5188-5199.
73. Halama N., Michel S., Kloor M., Zoernig I., Pommerencke T., von Knebel Doeberitz M., et al. The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. Cancer Immun 2009, 9:1.
74. Ali A.A., McMillan D.C., Matalka I.I., McNicol A.M., McArdle C.S. Tumour T-lymphocyte subset infiltration and tumour recurrence following curative resection for colorectal cancer. Eur J Surg Oncol 2004, 30(3):292-295.
75. Menon A.G., Janssen-van Rhijn C.M., Morreau H., Putter H., Tollenaar R.A., van de Velde C.J., et al. Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest 2004, 84(4):493-501.
76. Canna K., McArdle P.A., McMillan D.C., McNicol A.M., Smith G.W., McKee R.F., et al. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 2005, 92(4):651-654.
77. Diederichsen A.C., Hjelmborg J.B., Christensen P.B., Zeuthen J., Fenger C. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother 2003, 52(7):423-428.
78. Loddenkemper C., Schernus M., Noutsias M., Stein H., Thiel E., Nagorsen D. In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer. J Transl Med 2006, 4:52.
79. Salama P., Phillips M., Grieu F., Morris M., Zeps N., Joseph D., et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009, 27(2):186-192.
80. Frey D.M., Droeser R.A., Viehl C.T., Zlobec I., Lugli A., Zingg U., et al. High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer 2010, 126(11):2635-2643.
81. Suzuki H., Chikazawa N., Tasaka T., Wada J., Yamasaki A., Kitaura Y., et al. Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer. Cancer Immunol Immunother 2010, 59(5):653-661.
82. Correale P., Rotundo M.S., Del Vecchio M.T., Remondo C., Migali C., Ginanneschi C., et al. Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother 2010, 33(4):435-441.
83. Pages F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005, 353(25):2654-2666.
84. Oberg A., Samii S., Stenling R., Lindmark G. Different occurrence of CD8+, CD45R0+, and CD68+ immune cells in regional lymph node metastases from colorectal cancer as potential prognostic predictors. Int J Colorectal Dis 2002, 17(1):25-29.
85. Pages F., Kirilovsky A., Mlecnik B., Asslaber M., Tosolini M., Bindea G., et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009, 27(35):5944-5951.
86. Mlecnik B., Tosolini M., Kirilovsky A., Berger A., Bindea G., Meatchi T., et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011, 29(6):610-618.
87. Naito Y., Saito K., Shiiba K., Ohuchi A., Saigenji K., Nagura H., et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998, 58(16):3491-3494.
88. Funada Y., Noguchi T., Kikuchi R., Takeno S., Uchida Y., Gabbert H.E. Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep 2003, 10(2):309-313.
89. Prall F., Duhrkop T., Weirich V., Ostwald C., Lenz P., Nizze H., et al. Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol 2004, 35(7):808-816.
90. Canna K., McMillan D.C., McKee R.F., McNicol A.M., Horgan P.G., McArdle C.S. Evaluation of a cumulative prognostic score based on the systemic inflammatory response in patients undergoing potentially curative surgery for colorectal cancer. Br J Cancer 2004, 90(9):1707-1709.
91. Oshikiri T., Miyamoto M., Morita T., Fujita M., Miyasaka Y., Senmaru N., et al. Tumor-associated antigen recognized by the 22-1-1 monoclonal antibody encourages colorectal cancer progression under the scanty CD8+ T cells. Clin Cancer Res 2006, 12(2):411-416.
92. Zlobec I., Terracciano L.M., Lugli A. Local recurrence in mismatch repair-proficient colon cancer predicted by an infiltrative tumor border and lack of CD8+ tumor-infiltrating lymphocytes. Clin Cancer Res 2008, 14(12):3792-3797.
93. Camus M., Tosolini M., Mlecnik B., Pages F., Kirilovsky A., Berger A., et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 2009, 69(6):2685-2693.
94. Lugli A., Karamitopoulou E., Panayiotides I., Karakitsos P., Rallis G., Peros G., et al. CD8+ lymphocytes/tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer. Br J Cancer 2009, 101(8):1382-1392.
95. Tachibana T., Onodera H., Tsuruyama T., Mori A., Nagayama S., Hiai H., et al. Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin Cancer Res 2005, 11(20):7322-7327.
96. Nakayama Y., Nagashima N., Minagawa N., Inoue Y., Katsuki T., Onitsuka K., et al. Relationships between tumor-associated macrophages and clinicopathological factors in patients with colorectal cancer. Anticancer Res 2002, 22(6C):4291-4296.
97. Khorana A.A., Ryan C.K., Cox C., Eberly S., Sahasrabudhe D.M. Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with stage II and stage III colon carcinoma: a role for the host response in prognosis. Cancer 2003, 97(4):960-968.
98. Inoue Y., Nakayama Y., Minagawa N., Katsuki T., Nagashima N., Matsumoto K., et al. Relationship between interleukin-12-expressing cells and antigen-presenting cells in patients with colorectal cancer. Anticancer Res 2005, 25(5):3541-3546.
99. Tan S.Y., Fan Y., Luo H.S., Shen Z.X., Guo Y., Zhao L.J. Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer. World J Gastroenterol 2005, 11(8):1210-1214.
100. Zhou Q., Peng R.Q., Wu X.J., Xia Q., Hou J.H., Ding Y., et al. The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer. J Transl Med 2010, 8:13.
101. Nagorsen D., Voigt S., Berg E., Stein H., Thiel E., Loddenkemper C. Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J Transl Med 2007, 5:62.
102. Gulubova M., Vlaykova T. Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer. J Gastroenterol Hepatol 2009, 24(7):1265-1275.
103. Pretlow T.P., Keith E.F., Cryar A.K., Bartolucci A.A., Pitts A.M., Pretlow T.G., et al. Eosinophil infiltration of human colonic carcinomas as a prognostic indicator. Cancer Res 1983, 43(6):2997-3000.
104. Fisher E.R., Paik S.M., Rockette H., Jones J., Caplan R., Fisher B. Prognostic significance of eosinophils and mast cells in rectal cancer: findings from the National Surgical Adjuvant Breast and Bowel Project (protocol R-01). Hum Pathol 1989, 20(2):159-163.
105. Acikalin M.F., Oner U., Topcu I., Yasar B., Kiper H., Colak E. Tumour angiogenesis and mast cell density in the prognostic assessment of colorectal carcinomas. Dig Liver Dis 2005, 37(3):162-169.
106. Ambe K., Mori M., Enjoji M. S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer 1989, 63(3):496-503.
107. Nakayama Y., Inoue Y., Minagawa N., Katsuki T., Nagashima N., Onitsuka K., et al. Relationships between S-100 protein-positive cells and clinicopathological factors in patients with colorectal cancer. Anticancer Res 2003, 23(6a):4423-4426.
108. Dadabayev A.R., Sandel M.H., Menon A.G., Morreau H., Melief C.J., Offringa R., et al. Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells. Cancer Immunol Immunother 2004, 53(11):978-986.
109. Sandel M.H., Dadabayev A.R., Menon A.G., Morreau H., Melief C.J., Offringa R., et al. Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res 2005, 11(7):2576-2582.
110. Fernandez-Acenero M.J., Galindo-Gallego M., Sanz J., Aljama A. Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma. Cancer 2000, 88(7):1544-1548.
111. Inoue T., Plieth D., Venkov C.D., Xu C., Neilson E.G. Antibodies against macrophages that overlap in specificity with fibroblasts. Kidney Int 2005, 67(6):2488-2493.